Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2016 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks: does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? We need to look for any statement from management that indicates an escalation in the unit size of their business. The transcript is about Waters Corp's Q3 2016 earnings call. Management discusses various aspects: biopharmaceutical growth, China, recurring revenue, TA Instruments, etc. But we need to find if they explicitly say that the size of individual deals, orders, or contracts is increasing. Scanning the transcript: Chris O'Connell talks about growth in biopharma, China, recurring revenue. He mentions "continued strong performance in our core biopharmaceutical business" and "sustained momentum in China". He talks about product lines like ACQUITY Arc, Xevo TQ-S micro, etc. He mentions "strong double-digit sales growth in China" and "growth across all of our markets and product lines". But does he say that the size of individual orders or contracts is escalating? He does not seem to mention anything about deal size, order size, or that new engagements are larger than before. Gene Cassis talks about financials, margins, etc. No mention of deal size escalation. There is a mention of "pent-up demand" in industrial markets, but that's about potential future growth, not about current escalation. The question specifically asks about "successive engagements of the same kind coming in at progressively larger size". There is no such statement. Management talks about growth in revenue, but that could be from more units, not larger units. They don't compare the size of current deals to past deals. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.